Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.56 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.56 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.56 |
| ▸ | PGR | P06401 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 5/20 | 0.36 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.36 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2633043 | 0.84 | — | — | |
| SCHEMBL24880069 | 0.84 | — | — | |
| SCHEMBL268013 | 0.84 | — | — | |
| SCHEMBL21022226 | 0.82 | — | — | |
| SCHEMBL24509151 | 0.82 | — | — | |
| SCHEMBL662116 | 0.82 | — | — | |
| SCHEMBL23746779 | 0.80 | CACNA2D1 (0.42) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL24218208 | 0.80 | CACNA2D1 (0.46) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL22779212 | 0.80 | CACNA2D1 (0.46) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL11726366 | 0.80 | CACNA2D1 (0.46) | CACNA2D1CACNB3CACNA1CPGRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108623577-B | Preparation method of amonebvir and intermediate thereof | 山东百诺医药股份有限公司 | 2020-09-25 | — | — | CN | claimed |
| WO-2005058861-A1 | PROCESS FOR PREPARING SIMVASTATIN. | UK CHEMIPHARM CO., LTD. (KR) | 2005-06-30 | — | — | WO | claimed |
| EP-1484334-A2 | Process for producing phosphite | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-12-08 | — | — | EP | claimed |
| US-20040225145-A1 | Process for producing phosphite | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-11-11 | — | — | US | claimed |
| EP-0138669-B1 | PROCESS FOR THE PREPARATION OF SILANES FROM METHYLDICHLOROSILANE AND CHLOROSILANES | RHONE-POULENC CHIMIE (FR) | 1988-08-10 | — | — | EP | claimed |
| EP-0138670-B1 | PROCESS FOR THE PREPARATION OF SILANES WITH A SI-H BOND BY REDISTRIBUTION | RHONE-POULENC CHIMIE (FR) | 1988-05-25 | — | — | EP | claimed |
| US-4746752-A | QUATERNARY OR TERTIARY AMINE CATALYST | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1988-05-24 | — | — | US | claimed |
| US-4605543-A | DISTRIBUTION AND DISPROPORTIONATION CATALYSIS | RHONE-POULENC SPECIALITIES CHIMIQUES (FR) | 1986-08-12 | — | — | US | claimed |
| EP-0138670-A2 | Process for the preparation of silanes with a Si-H bond by redistribution | RHONE-POULENC CHIMIE (FR) | 1985-04-24 | — | — | EP | claimed |
| EP-0138669-A2 | Process for the preparation of silanes from methyldichlorosilane and chlorosilanes | RHONE-POULENC CHIMIE (FR) | 1985-04-24 | — | — | EP | claimed |
| US-12545685-B2 | Dispiropyrrolidine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-02-10 | — | — | US | disclosed |
| US-20240246989-A1 | DISPIROPYRROLIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-07-25 | — | — | US | disclosed |
| CN-111892592-B | JAK kinase inhibitors and uses thereof | 江苏柯菲平医药股份有限公司 | 2023-09-19 | — | — | CN | disclosed |
| US-20230203070-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2023-06-29 | — | — | US | disclosed |
| US-20230203070-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2023-06-29 | — | — | US | disclosed |
| US-4605543-A | DISTRIBUTION AND DISPROPORTIONATION CATALYSIS | RHONE-POULENC SPECIALITIES CHIMIQUES (FR) | 1986-08-12 | — | — | US | disclosed |
| EP-0138670-A2 | Process for the preparation of silanes with a Si-H bond by redistribution | RHONE-POULENC CHIMIE (FR) | 1985-04-24 | — | — | EP | disclosed |
| EP-0138669-A2 | Process for the preparation of silanes from methyldichlorosilane and chlorosilanes | RHONE-POULENC CHIMIE (FR) | 1985-04-24 | — | — | EP | disclosed |
| US-4427586-A | ANTI-BACTERIAL AGENTS AND ENZYME INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1984-01-24 | — | — | US | disclosed |
| EP-0052299-A1 | 2-Oxoazetidine derivatives and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1982-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545685-B2 | Dispiropyrrolidine derivatives | TP53, MDM2, TP53BP1 | CACNA2D1 2138/4885CACNB3 2827/4885CACNA1C 3429/4885 |
| US-20230203070-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | HTR1A, HTR6, HTR1B | CACNA2D1 2354/4885CACNB3 2108/4885CACNA1C 1596/4885 |
| US-20040225145-A1 | Process for producing phosphite | PHOSPHO1, PLCG1, PLCG2 | CACNA2D1 1990/4885CACNB3 4269/4885CACNA1C 3930/4885 |
| US-20240246989-A1 | DISPIROPYRROLIDINE DERIVATIVES | MDM2, TP53, TP53BP1 | CACNA2D1 2915/4885CACNB3 4282/4885CACNA1C 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.